Jan 15 (Reuters) - Mesoblast Ltd MSB.AX :
* US FDA AGREED TO SELECT RYONCIL AS COMMERCIAL NAME FOR ITS LEAD ALLOGENEIC CELL THERAPY REMESTEMCEL-L
Jan 15 (Reuters) - Mesoblast Ltd MSB.AX :
* US FDA AGREED TO SELECT RYONCIL AS COMMERCIAL NAME FOR ITS LEAD ALLOGENEIC CELL THERAPY REMESTEMCEL-L